Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Six month progression free survival (PFS6) in patients with recurrent high grade gliomas treated with bevacizumab and metronomic dose temozolomide, compared to historical controls (PFS6 = 10%).
Inclusion criteria
- Patients with a recurrent high grade glioma (after primary treatment)